LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

Начало・Списък с акции・MacroGenics Inc

MacroGenics Inc

Затворен

СекторЗдравеопазване

4.13 -0.96

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.05

Максимум

4.25

Ключови измерители
By Trading Economics
Приходи	-23M -37M
Продажби	-20M 21M
EPS	-0.58
Марж на печалбата	-177.011
Служители	293
EBITDA	-17M -32M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+52.16% upside

Дивиденти
By Dow Jones
Следващи печалби	12.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	100M 288M
Предишно отваряне	5.09
Предишно затваряне	4.13

Настроения в новините

By Acuity

12%

88%

12 / 344 Класиране в Healthcare

MacroGenics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

1.06.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1.06.2026 г., 23:38 ч. UTC

Придобивния, сливания и поглъщания

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1.06.2026 г., 23:37 ч. UTC

Пазарно говорене

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1.06.2026 г., 23:01 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

1.06.2026 г., 23:01 ч. UTC

Пазарно говорене

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1.06.2026 г., 22:08 ч. UTC

Придобивния, сливания и поглъщания

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1.06.2026 г., 22:01 ч. UTC

Придобивния, сливания и поглъщания

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1.06.2026 г., 22:01 ч. UTC

Придобивния, сливания и поглъщания

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1.06.2026 г., 21:55 ч. UTC

Придобивния, сливания и поглъщания

Greg Abel's Week Is Off to Quite a Start -- WSJ

1.06.2026 г., 21:53 ч. UTC

Пазарно говорене

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1.06.2026 г., 21:22 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Tech, Media & Telecom Roundup: Market Talk

1.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

1.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

1.06.2026 г., 20:46 ч. UTC

Придобивния, сливания и поглъщания

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1.06.2026 г., 20:22 ч. UTC

Придобивния, сливания и поглъщания

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1.06.2026 г., 20:21 ч. UTC

Придобивния, сливания и поглъщания

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1.06.2026 г., 20:21 ч. UTC

Придобивния, сливания и поглъщания

Array Digital Infrastructure Declares $11 Special Div

1.06.2026 г., 20:20 ч. UTC

Придобивния, сливания и поглъщания

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1.06.2026 г., 19:40 ч. UTC

Пазарно говорене

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1.06.2026 г., 19:28 ч. UTC

Пазарно говорене

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1.06.2026 г., 19:01 ч. UTC

Пазарно говорене

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1.06.2026 г., 18:58 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1.06.2026 г., 18:54 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1.06.2026 г., 18:33 ч. UTC

Пазарно говорене

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1.06.2026 г., 18:32 ч. UTC

Пазарно говорене

Precious Metals Fall to Start June -- Market Talk

1.06.2026 г., 18:00 ч. UTC

Придобивния, сливания и поглъщания

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1.06.2026 г., 17:18 ч. UTC

Пазарно говорене

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1.06.2026 г., 17:18 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

1.06.2026 г., 17:10 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

MacroGenics Inc Прогноза

Ценова цел

By TipRanks

52.16% нагоре

12-месечна прогноза

Среден 6.33 USD 52.16%

Висок 9 USD

Нисък 4 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за MacroGenics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на MacroGenics Inc през последните 3 месеца.

Настроение

By Acuity

12 / 344 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.